🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Chūōku
Clinical trial register · Japan

Clinical Trials in Chūōku, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2472 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:48 UTC
2472
Studies in scope
all four open statuses
1255
Recruiting now
open to new participants
347
Lead sponsors
across recruiting studies
Top sites
Chūōku 35 Fukuoka 33 Nagoya 19 Chiba 19 Kobe 19
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca92 Eli Lilly and Company35 Daiichi Sankyo14 Janssen Research & Development, LLC13 EMD Serono Research & Development Institute, Inc.7 Clear sponsor filter
Site location
Chūōku35 Fukuoka33 Nagoya19 Chiba19 Kobe19
All 190 locations
Target enrolment
to

Trials with a site in Chūōku

35 of 2472 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
NCT07794579Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
DrugOrforglipron
Eli Lilly and Company
Phase 3
2,001
Chūōku, Suita-shi, Tsuchiura
2026-08-26
Recruiting
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT07759245Pulmonary Disease, Chronic Obstructive
DrugBrenipatide
Eli Lilly and Company
Phase 2
606
Chūōku, Fukuoka, Iizuka, Osaka, Sendai, Ube
2026-08-07
Recruiting
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
NCT07602582Alzheimer Disease, Dementia, Plaque, Amyloid
DrugDonanemab
Eli Lilly and Company
Phase 3
550
Chūōku, Hachiōji, Ōbu, Shinjuku, Shinjyuku, tabashi City
2026-05-22
Recruiting
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
NCT07545759Irritable Bowel Syndrome, Diarrhea
DrugBrenipatide
Eli Lilly and Company
Phase 2
531
Chūōku, Fujiidera, Isehara, Kobe, Kumamoto, Sapporo, Shinjuku-Ku
2026-05-06
Recruiting
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
NCT07545772Irritable Bowel Syndrome, Constipation
DrugBrenipatide
Eli Lilly and Company
Phase 2
342
Chūōku, Isehara, Kobe, Sapporo, Shinjuku-Ku
2026-04-29
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
NCT07392190Overweight, Obesity
DrugEloralintide
Eli Lilly and Company
Phase 3
900
Chūōku, Izumisano, Kawasaki, Kisarazu, Kure, Kyoto, Matsuyama, Osaka
2026-02-10
Recruiting
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
NCT07353931Osteoarthritis, Overweight or Obesity
DrugEloralintide
Eli Lilly and Company
Phase 3
900
Chiba, Chūōku, Kitakyushu-Shi, Miyazaki, Nagareyama, Ōita, Saitama, Sashima
2026-02-09
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886Obesity, Overweight
DrugEloralintide
Eli Lilly and Company
Phase 3
1,980
Adachi-ku, Chūōku, Fukuoka, Minato, Mitaka, Suita-shi, Tokyo
2026-02-06
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
NCT07282600Overweight, Obesity
DrugEloralintide
Eli Lilly and Company
Phase 3
1,035
Chigasaki, Chūōku, Kamakura, Kasuya-gun, Kawaguchi, Kita-ku, Mihama-ku,Chiba City, Naha
2025-12-15
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Chūōku, Fukuoka, Hirosaki, Kanazawa, Kashiwa, Kawasaki, Kita-ku, Kobe
2025-12-12
Recruiting
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
NCT07269210Severe Hypertriglyceridemia
Eli Lilly and Company
Phase 2
60
Chūōku, Kamakura-shi, Suita-shi
2025-12-08
Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
DrugOrforglipron
Eli Lilly and Company
Phase 3
7,140
Chūōku, Hamadayama, Suginami-ku, Izumisano, Kobe, Kofu, Kumamoto, Shinjuku-ku, Takarazuka
2025-12-01
Recruiting
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
NCT07219173Asthma
DrugBrenipatide
Eli Lilly and Company
Phase 2
531
Chūōku, Habikino, Iizuka, Kagoshima, Kanazawa, Katsushika-ku, Nagoya, Narita
2025-10-22
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
DrugsMIRV·Pegylated liposomal doxorubicin·Topotecan·Gemcitabine
Eli Lilly and Company
Phase 3
1,630
Akashi, Chūōku, Fukuoka, Hidaka, Kagoshima, Kashiwa, Kōtoku, Nagoya
2025-10-22
Recruiting
A Study of Brenipatide in Participants With Alcohol Use Disorder
NCT07219953Alcohol Use Disorder
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,100
Chūōku, Fukuoka, Karatsu, Kobe, Nagasaki, Nakano, Nishi, Shibuya City
2025-10-16
Recruiting
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
NCT07219966Alcohol Use Disorder
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,100
Chūōku, Fukuoka, Karatsu, Kariya, Kobe, Nagasaki, Nishi, Setagaya City
2025-10-15
Recruiting
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
NCT07202884Urinary Incontinence,Stress
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,000
Arakawa City, Chiba, Chiyoda City, Chūōku, Higashiibaraki, Itabashiku, Kitakyushu, Matsudo
2025-09-30
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Akita, Amagasaki, Bunkyō, Chūōku, Fujisawa, Fukuoka, Gifu, Hachioji-shi
2025-09-02
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472Obesity, Overweight, Type 2 Diabetes
DrugOrforglipron
Eli Lilly and Company
Phase 3
600
Chitose, Chūōku, Mihama-ku,Chiba City, Shinjuku-ku, Suita-shi, Takamatsu, Tokyo, Tsuchiura
2025-05-19
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
NCT06972459Obesity, Overweight
DrugOrforglipron
Eli Lilly and Company
Phase 3
800
Chitose, Chūōku, Mihama-ku,Chiba City, Shinjuku-ku, Suita-shi, Takamatsu, Tokyo, Tsuchiura
2025-05-15
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT06993792Obesity, Overweight, Type 2 Diabetes
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,400
Chitose, Chūōku, Mihama-ku,Chiba City, Shinjuku-ku, Suita-shi, Takamatsu, Tokyo, Tsuchiura
2025-05-15
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435Hypertension, Overweight or Obesity
DrugOrforglipron
Eli Lilly and Company
Phase 3
487
Chūōku, Kamakura-shi, Matsuyama, Yamato-shi
2025-04-30
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
NCT06952530Hypertension
DrugOrforglipron
Eli Lilly and Company
Phase 3
487
Chūōku, Kamakura-shi, Matsuyama, Yamato-shi
2025-04-30
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
NCT06948422Hypertension
DrugOrforglipron
Eli Lilly and Company
Phase 3
974
Chūōku, Kamakura-shi, Matsuyama, Yamato-shi
2025-04-30
Active, closed
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895Type 1 Diabetes, Obesity, Overweight
DrugTirzepatide
Eli Lilly and Company
Phase 3
905
Chūōku, Ebina, Fukuoka, Hachioji-shi, Kamakura-shi, Kashiwara, Kasugai, Kisarazu
2025-04-25
Active, closed
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153Alzheimer's Disease
DrugRemternetug
Eli Lilly and Company
Phase 3
1,400
Bunkyō City, Chūōku, Fujisawa, Fukuoka, Hachiōji, Himeji, Imabari, Kobe
2024-10-24
Recruiting
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
NCT06561685Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
DrugsNab-paclitaxel·Pemetrexed·Paclitaxel·Cisplatin
Eli Lilly and Company
Phase 1
340
Chūōku, Kashiwa, Kōtō City, Nagaizumi-cho,Sunto-gun, Nagoya
2024-09-19
Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
420
Chūōku, Kashiwa, Chiba, Kōtō City, Nagoya
2024-07-01
Active, closed
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
NCT06292013Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
DrugLepodisiran
Eli Lilly and Company
Phase 3
17,300
Asahi, Asahikawa, Chikushino-shi, Chūō, Chūōku, Fukuoka, Hakodate, Hakusan
2024-03-05
Active, closed
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
NCT06238479Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
490
Chūōku, Kashiwa, Kōtō City, Kyoto
2024-03-05
Active, closed
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512Obesity, Overweight
DrugTirzepatide
Eli Lilly and Company
Phase 3
15,374
Chūōku, Fukuoka, Izumisano, Kyoto, Minatoku, Onga-gun, Osaka, Uji
2022-10-11
Active, closed
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054Breast Neoplasms
DrugsImlunestrant·Tamoxifen·Exemestane·Anastrozole
Eli Lilly and Company
Phase 3
8,000
Bunkyō City, Chiba, Chūōku, Fukuoka, Fukushima, Fukuyama, Gifu, Hachioji-shi
2022-10-04
Recruiting
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
NCT05307705Breast Cancer
DrugsAnastrozole, Exemestane·Imlunestrant·Abemaciclib·Letrozole
Eli Lilly and Company
Phase 1
260
Chūōku, Kōtō City, Kyoto, Nagoya
2022-05-11
Active, closed
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
NCT05026866Alzheimer Disease
DrugDonanemab
Eli Lilly and Company
Phase 3
2,996
Bunkyō City, Chūōku, Hachiōji, Osaka, Ōbu, Shinjuku, Shinjuku-ku, Suita-shi
2021-08-27
Recruiting
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
NCT05999994Neoplasms, Child, Adolescent
DrugsRamucirumab·Vinorelbine·Abemaciclib·Temozolomide
Eli Lilly and Company
Phase 2
105
Chūōku, Fukuoka, Kobe
2020-01-22
Rows per page Showing 1–35 of 35
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-japan/city/ch-ku

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,472 studies in total at the last sync on 26 Sep 2026, 19:48 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 35 of those studies with a site in Chūōku that also match the filters currently applied.

How many clinical trials are recruiting in Chūōku?

22 of the 35 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:48 UTC sync. A further 0 have not yet opened recruitment, 13 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Chūōku), 35 studies
PhaseStudiesRecruitingShare
Phase 3251371.4%
Phase 26617.1%
Phase 14311.4%

Most active sponsors

Lead sponsors with the most studies (Chūōku)
Lead sponsorStudiesRecruiting
Eli Lilly and Company3522
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.